These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [New trends in rheumatology. The Danish Society of Rheumatology]. Andersen LS; Gam AN; Hansen A; Kollerup G; Rasmussen C; Rasmussen JM; Schiøttz-Christensen B; Slot O; Thamsborg G Ugeskr Laeger; 2003 Mar; 165(12):1255. PubMed ID: 12701305 [No Abstract] [Full Text] [Related]
5. [Current status of methotrexate]. Fiehn C Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022 [No Abstract] [Full Text] [Related]
6. [Continuous quick development of rheumatology]. Madsen OR; Terslev L; Tarp U; Jacobsen S; Ostergaard M Ugeskr Laeger; 2009 Mar; 171(13):1092. PubMed ID: 19321087 [No Abstract] [Full Text] [Related]
7. Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort? Peloso PM J Rheumatol; 2004 Jan; 31(1):8-11. PubMed ID: 14705210 [No Abstract] [Full Text] [Related]
8. Setting the research agenda for future clinical trials on the use of biologics in rheumatology. Silman A; Rudkin S; Walley T Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870 [No Abstract] [Full Text] [Related]
9. Advances in targeted therapies XII. Preface. Breedveld FC; Kalden JR; Smolen JS Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1. PubMed ID: 21339210 [No Abstract] [Full Text] [Related]
10. The history of the use of sulphasalazine in rheumatology. Amos RS Br J Rheumatol; 1995 Nov; 34 Suppl 2():2-6. PubMed ID: 8535643 [TBL] [Abstract][Full Text] [Related]
14. [Biosimilars]. Burmester GR; Müller-Ladner U Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433 [No Abstract] [Full Text] [Related]
15. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade. Yelin E; Katz P Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010 [No Abstract] [Full Text] [Related]
16. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207 [TBL] [Abstract][Full Text] [Related]
17. [Evidence based medicine in rheumatology]. Gause A; Raspe HH Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877 [No Abstract] [Full Text] [Related]
18. [Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)]. Tsurko VV; Preobrazhenskiĭ DV; Ob ukhova OA Ter Arkh; 2003; 75(5):64-70. PubMed ID: 12847902 [No Abstract] [Full Text] [Related]
19. Rheumatic Disease Clinics of North America. Drug safety: managing innovation in rheumatology. Foreword. Weisman MH Rheum Dis Clin North Am; 2012 Nov; 38(4):ix-x. PubMed ID: 23137584 [No Abstract] [Full Text] [Related]
20. [The future of RA treatment]. Matsubara T Ryumachi; 1997 Oct; 37(5):679-80. PubMed ID: 9396369 [No Abstract] [Full Text] [Related] [Next] [New Search]